C2A - Expanding Opportunities for Pharmacometrics in the Era of Digital Health

Sunday, October 19, 2025

2:00 PM - 3:30 PM MDT

Location: Colorado B-D

Chair(s)

GL

Grace Lee, PhD (she/her/hers)

Quantitative Medicine Scientist
Critical Path Institute
Tucson, Arizona, United States

Speaker(s)

Alice Carr, PhD (she/her/hers)

Postdoctoral Fellow
Alberta Diabetes Institute, University of Alberta, Canada
LH

Lucy Hutchinson, PhD (she/her/hers)

Digital Products and Insights Principal Data Scientist
Data, Analytics and Research, Roche Information Solutions
Basel, Basel-Stadt, Switzerland
Logan Brooks, MS

Principal Scientist (AI / Pharmacometrics)
Genentech, United States

Panelist(s)

Mingyuan Wang, PhD

Quantitative Medicine Scientist
critical path institute, United States

Disclosure(s):

Grace V. Lee, PhD: No financial relationships to disclose

Alice Carr, PhD: No financial relationships to disclose

Lucy Hutchinson, PhD: No financial relationships to disclose

Logan Brooks, MS: No relevant disclosure to display

Mingyuan Wang, PhD: No financial relationships to disclose

Description of session (include background & scientific importance): Pharmacometrics and Model-informed Drug Development continue to grow in scope as new data collection methodologies and computational and analytical tools are developed. In particular, the implementation of digital health technologies (DHTs) in drug development and diagnostics to gather objective, high-frequency, and real-world data provides MIDD scientists with new opportunities to leverage quantitative methodologies including PKPD, QSP, and AI/ML. While DHTs are typically associated with wearable motion sensors such as smartwatches and smartphones, the FDA definition of DHTs extends to a broader class of computing platforms, connectivity, software, and sensors for health care and related uses.

This session will provide an accessible, introductory-level overview of the current digital health landscape from industry, academic, and nonprofit perspectives, and the opportunities and strategies that exist for leveraging DHT data for MIDD. In addition, we will illustrate how the use of DHTs is beneficial for expanding the scope of quantitative tools, leading to further opportunities for the use of advanced models across a variety of contexts.

Learning Objectives:

Upon completion, participants will be able to describe the current landscape of digital health in model-informed drug development, including major definitions, opportunities, and challenges present in the field today. Furthermore, they will gain knowledge of novel approaches for addressing DHT data using pharmacometrics and AI/ML and understand the implications of DHTs on the future of MIDD in drug development and diagnostics.

Presentations:

2:00 PM - 2:20 PM MDT

Continuous Progress: Harnessing Continuous Glucose Monitoring to Enhance Early-Stage Type 1 Diabetes Clinical Trials
Speaker: Alice Carr, PhD (she/her/hers) – Alberta Diabetes Institute, University of Alberta
2:20 PM - 2:40 PM MDT

AI-Driven Insights: Leveraging Digital Health Technologies for Enhanced Clinical Drug Development
Speaker: Logan Brooks, MS – Genentech
2:40 PM - 3:00 PM MDT

Digital Health: from Drug Development to Diagnostics
Speaker: Lucy Hutchinson, PhD (she/her/hers) – Data, Analytics and Research, Roche Information Solutions
3:00 PM - 3:30 PM MDT

Panel - Expanding Opportunities for Pharmacometrics in the Era of Digital Health
Panelist: Alice Carr, PhD (she/her/hers) – Alberta Diabetes Institute, University of Alberta
Panelist: Logan Brooks, MS – Genentech
Panelist: Lucy Hutchinson, PhD (she/her/hers) – Data, Analytics and Research, Roche Information Solutions
Panelist: Mingyuan Wang, PhD – critical path institute